Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH
about
Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificitiesThe human paraoxonase gene cluster as a target in the treatment of atherosclerosisInduction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirinParaoxonase 1 and homocysteine metabolism.A Novel Anti-Inflammatory Effect for High Density Lipoprotein.Increased presence of oxidized low-density lipoprotein in the left ventricular blood of subjects with cardiovascular disease.Water-Soluble Components of Sesame Oil Reduce Inflammation and Atherosclerosis.Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases.The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux.Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.Molecular dynamics simulation of human serum paraoxonase 1 in DPPC bilayer reveals a critical role of transmembrane helix H1 for HDL association.TagSNP analyses of the PON gene cluster: effects on PON1 activity, LDL oxidative susceptibility, and vascular disease.Broad-spectrum antioxidant peptides derived from His residue-containing sequences present in human paraoxonase 1.The role of paraoxonase 1 in regulating high-density lipoprotein functionality during aging.
P2860
Q24298200-7A04F9DA-DC2C-4DED-8EED-72FD7670E60BQ26824356-6FF48BCA-AAFE-480A-A630-B69E94DBFD04Q28570302-A7135B03-777E-44EA-A6C4-402B743C8D9EQ30417352-06707735-DA61-4FCC-A1C8-359DDB006097Q35872393-51496BBF-CBF3-429A-9EDA-B8FBDE52FB88Q36748282-6791B8FD-A564-4DDF-B274-6743AAE9C688Q37102203-117A69C2-996D-4DDE-82A0-E75D97D4DE1AQ38062539-9E980CFB-7AFF-401B-AD79-E66F8E83210BQ40331033-A0698B67-83C8-453C-B38F-B22283EE3235Q41115717-95AE1F73-B9A2-424F-9E85-C317A70392B9Q45224671-38E1B4FC-E0F2-4510-8EBB-4AB56BA4B7B3Q46941197-8E9A331E-9449-401E-A2FC-ED444E07E1E3Q46975817-F99A5155-121B-4076-89FA-CD30297C2939Q48024855-31ED7F59-A14D-461D-BA54-30FCD8B15936
P2860
Purified human serum PON1 does not protect LDL against oxidation in the in vitro assays initiated with copper or AAPH
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Purified human serum PON1 does ...... initiated with copper or AAPH
@ast
Purified human serum PON1 does ...... initiated with copper or AAPH
@en
Purified human serum PON1 does ...... initiated with copper or AAPH
@en-gb
Purified human serum PON1 does ...... initiated with copper or AAPH
@nl
type
label
Purified human serum PON1 does ...... initiated with copper or AAPH
@ast
Purified human serum PON1 does ...... initiated with copper or AAPH
@en
Purified human serum PON1 does ...... initiated with copper or AAPH
@en-gb
Purified human serum PON1 does ...... initiated with copper or AAPH
@nl
prefLabel
Purified human serum PON1 does ...... initiated with copper or AAPH
@ast
Purified human serum PON1 does ...... initiated with copper or AAPH
@en
Purified human serum PON1 does ...... initiated with copper or AAPH
@en-gb
Purified human serum PON1 does ...... initiated with copper or AAPH
@nl
P2093
P2860
P3181
P1476
Purified human serum PON1 does ...... initiated with copper or AAPH
@en
P2093
Bert N La Du
Dragomir I Draganov
John F Teiber
P2860
P304
P3181
P356
10.1194/JLR.M400213-JLR200
P407
P577
2004-12-01T00:00:00Z